Patents Assigned to Neuracle Science Co., Ltd.
  • Publication number: 20250067755
    Abstract: The present disclosure relates to a method of diagnosing a mood disorder in a subject comprising measuring serum FAM19A5 concentration with an antagonist (e.g., an antibody or antigen-binding fragment thereof) that specifically binds to FAM19A5. The present disclosure also relates to a method of treating a mood disorder in a subject in need thereof comprising administering to the subject an FAM19A5 antagonist.
    Type: Application
    Filed: July 18, 2024
    Publication date: February 27, 2025
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Jae Young SEONG, Byung Joo HAM, Min-Hyeok LEE, Nui HA
  • Patent number: 12215338
    Abstract: The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: February 4, 2025
    Assignees: Neuracle Science Co., Ltd., Neuracle Genetics
    Inventors: Jong-Mook Kim, Dong Sik Kim, Juwon Shim, Soon-gu Kwon
  • Publication number: 20240360209
    Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.
    Type: Application
    Filed: April 1, 2024
    Publication date: October 31, 2024
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Bongcheol KIM, Wonkyum KIM, Jeongwon YOON, Junho CHUNG, Junyeong JIN, Eunhwoi YOU
  • Patent number: 12077579
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: September 3, 2024
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Jae-Keun Lee, Dong Sik Kim
  • Patent number: 12072339
    Abstract: The present disclosure relates to a method of diagnosing a mood disorder in a subject comprising measuring serum FAM19A5 concentration with an antagonist (e.g., an antibody or antigen-binding fragment thereof) that specifically binds to FAM19A5. The present disclosure also relates to a method of treating a mood disorder in a subject in need thereof comprising administering to the subject an FAM19A5 antagonist.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: August 27, 2024
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Jae Young Seong, Byung Joo Ham, Min-Hyeok Lee, Nui Ha
  • Publication number: 20240182555
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.
    Type: Application
    Filed: July 27, 2023
    Publication date: June 6, 2024
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Bongcheol KIM, Dong Sik KIM, Soon-gu KWON
  • Publication number: 20240166735
    Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
    Type: Application
    Filed: July 11, 2023
    Publication date: May 23, 2024
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Jae Young SEONG, Jong Ik HWANG, Woong SUN, Eun Bee CHO, Won-Ki KIM
  • Patent number: 11970532
    Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: April 30, 2024
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Wonkyum Kim, Jeongwon Yoon, Junho Chung, Junyeong Jin, Eunhwoi You
  • Publication number: 20230357378
    Abstract: The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.
    Type: Application
    Filed: April 17, 2023
    Publication date: November 9, 2023
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Bongcheol KIM, Dong Sik KIM, Soon-gu KWON
  • Publication number: 20230348584
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.
    Type: Application
    Filed: January 23, 2023
    Publication date: November 2, 2023
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Bongcheol KIM, Eun Bee CHO, Dong Sik KIM, Jae-Keun LEE, Soon-gu KWON, Jae Young SEONG, Juwon SHIM, Tae Woo KIM, Shin-hyuk KANG
  • Publication number: 20230287096
    Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.
    Type: Application
    Filed: March 2, 2023
    Publication date: September 14, 2023
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Bongcheol KIM, Jae-Keun LEE, Dong Sik KIM, Junho CHUNG, Junyeong JIN
  • Patent number: 11746149
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: September 5, 2023
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Dong Sik Kim, Soon-gu Kwon
  • Patent number: 11739141
    Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: August 29, 2023
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
  • Patent number: 11634484
    Abstract: The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: April 25, 2023
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Dong Sik Kim, Soon-Gu Kwon
  • Patent number: 11618783
    Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: April 4, 2023
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Jae-Keun Lee, Dong Sik Kim, Junho Chung, Junyeong Jin
  • Patent number: 11560425
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: January 24, 2023
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Eun Bee Cho, Dong Sik Kim, Jae-Keun Lee, Soon-gu Kwon, Jae Young Seong, Juwon Shim, Tae Woo Kim, Shin-hyuk Kang
  • Patent number: 11332521
    Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: May 17, 2022
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Jae Young Seong, Jong Ik Hwang, Eun Bee Cho, Junho Chung, Junyeong Jin, Tae Young Yune, Jee Youn Lee
  • Publication number: 20220073601
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.
    Type: Application
    Filed: September 14, 2021
    Publication date: March 10, 2022
    Applicant: Neuracle Science Co., Ltd.
    Inventors: Bongcheol KIM, Jae-Keun LEE, Dong Sik KIM
  • Patent number: 11248023
    Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: February 15, 2022
    Assignee: Neuracle Science Co., Ltd
    Inventors: Jae Young Seong, Jong-Ik Hwang, Dong-Hoon Kim, Gi Hoon Son, Yoo-Na Lee, Seongsik Yun, Arfaxad Reyes-Alcaraz
  • Publication number: 20210388382
    Abstract: The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv.
    Type: Application
    Filed: May 8, 2019
    Publication date: December 16, 2021
    Applicants: Neuracle Science Co., Ltd., Neuracle Genetics
    Inventors: Jong-Mook KIM, Dong Sik KIM, Juwon SHIM, Soon-gu KWON